MarketPulse

mental health treatment

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley's Oral MDMA Therapy Shows Promise in Social Anxiety, Outperforming Placebo

AtaiBeckley reports Phase 2a results for EMP-01 oral R-MDMA in social anxiety disorder, showing 49% responder rates and 38% symptom reduction versus 15% on placebo.
ATAIclinical trial resultssocial anxiety disorder
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges 40% on White House Push for Psychedelic Drug Approvals

Compass Pathways stock surges 40% following White House Executive Order accelerating FDA approval of its COMP360 psychedelic therapy for treatment-resistant depression.
CMPSFDA approvaltreatment-resistant depression
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley CEO to Present at Needham Conferences as Psychedelic Drug Advances

AtaiBeckley will showcase its FDA-designated breakthrough therapy BPL-003 at Needham conferences in April, advancing toward Phase 3 trials in 2026.
ATAItreatment-resistant depressionFDA Breakthrough Therapy Designation
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley's BPL-003 Shows Durable Antidepressant Benefits in Treatment-Resistant Depression

AtaiBeckley's BPL-003 nasal spray demonstrates rapid and sustained antidepressant effects in treatment-resistant depression Phase 2a trial, advancing toward Phase 3 launch in Q2 2026.
ATAIPhase 3 clinical trialtreatment-resistant depression